Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures

MLA

Vornicu, Ovidiu, et al. “Idarucizumab for the Treatment of Hemorrhage and Dabigatran Reversal in Patients Requiring Urgent Surgery or Procedures.” Expert Opinion on Biological Therapy, vol. 17, no. 10, Oct. 2017, pp. 1275–96. EBSCOhost, https://doi.org/10.1080/14712598.2017.1349749.

APA

Vornicu, O., Larock, A.-S., Dincq, A.-S., Douxfils, J., Dogné, J.-M., Mullier, F., & Lessire, S. (2017). Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opinion on Biological Therapy, 17(10), 1275–1296. https://doi.org/10.1080/14712598.2017.1349749

Chicago

Vornicu, Ovidiu, Anne-Sophie Larock, Anne-Sophie Dincq, Jonathan Douxfils, Jean-Michel Dogné, François Mullier, and Sarah Lessire. 2017. “Idarucizumab for the Treatment of Hemorrhage and Dabigatran Reversal in Patients Requiring Urgent Surgery or Procedures.” Expert Opinion on Biological Therapy 17 (10): 1275–96. doi:10.1080/14712598.2017.1349749.